CL2023001719A1 - Polipéptidos y usos de los mismos - Google Patents
Polipéptidos y usos de los mismosInfo
- Publication number
- CL2023001719A1 CL2023001719A1 CL2023001719A CL2023001719A CL2023001719A1 CL 2023001719 A1 CL2023001719 A1 CL 2023001719A1 CL 2023001719 A CL2023001719 A CL 2023001719A CL 2023001719 A CL2023001719 A CL 2023001719A CL 2023001719 A1 CL2023001719 A1 CL 2023001719A1
- Authority
- CL
- Chile
- Prior art keywords
- polypeptides
- pramlintide
- residues
- analogues
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125996P | 2020-12-16 | 2020-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001719A1 true CL2023001719A1 (es) | 2024-01-26 |
Family
ID=79287870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001719A CL2023001719A1 (es) | 2020-12-16 | 2023-06-14 | Polipéptidos y usos de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US12371464B2 (enExample) |
| EP (1) | EP4263586A1 (enExample) |
| JP (1) | JP7767428B2 (enExample) |
| KR (1) | KR20230120134A (enExample) |
| CN (1) | CN116685599A (enExample) |
| AR (1) | AR124391A1 (enExample) |
| AU (2) | AU2021399076B2 (enExample) |
| CA (1) | CA3204296A1 (enExample) |
| CL (1) | CL2023001719A1 (enExample) |
| CO (1) | CO2023009066A2 (enExample) |
| CR (1) | CR20230311A (enExample) |
| EC (1) | ECSP23052600A (enExample) |
| IL (1) | IL303578A (enExample) |
| MX (1) | MX2023007288A (enExample) |
| TW (1) | TW202241933A (enExample) |
| WO (1) | WO2022129254A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12371464B2 (en) | 2020-12-16 | 2025-07-29 | Medimmune Limited | Polypeptides and uses thereof |
| IL304214B2 (en) | 2021-01-20 | 2025-01-01 | Viking Therapeutics Inc | Compositions and methods for treating metabolic and liver disorders |
| KR102873595B1 (ko) | 2021-09-15 | 2025-10-22 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 장애의 치료를 위한 조성물 및 방법 |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| IL322661A (en) * | 2023-02-10 | 2025-10-01 | Hangzhou Sciwind Biosciences Co Ltd | Polypeptide and its history, composition containing them and their use |
| JP7755031B2 (ja) | 2023-11-30 | 2025-10-15 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬 |
| WO2025147628A2 (en) * | 2024-01-05 | 2025-07-10 | Indiana University Research And Technology Corporation | Dual amylin calcitonin receptor agonists |
| WO2025242620A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Polypeptide combinations and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004051014A1 (de) * | 2004-10-20 | 2006-04-27 | Rwth Aachen | Chemisch modifizierte Peptidanaloga |
| EP1996617A2 (en) * | 2006-03-15 | 2008-12-03 | Novo Nordisk A/S | Amylin derivatives |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| CN102197049B (zh) * | 2008-10-21 | 2015-03-25 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽衍生物 |
| US9205135B2 (en) * | 2009-09-22 | 2015-12-08 | University Of Miami | Podocyte pH modulation and uses thereof |
| WO2013059336A1 (en) * | 2011-10-18 | 2013-04-25 | Amylin Pharmaceuticals, Llc | Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties |
| MX2016007407A (es) * | 2013-12-13 | 2016-12-12 | Medimmune Ltd | Peptidos resistentes a proteasa. |
| JP6730278B2 (ja) * | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| KR20210091705A (ko) * | 2018-10-11 | 2021-07-22 | 인타르시아 세라퓨틱스 인코포레이티드 | 인간 아밀린 유사체 폴리펩타이드 및 사용 방법 |
| WO2020225781A1 (en) * | 2019-05-08 | 2020-11-12 | Auckland Uniservices Limited | Peptide conjugate amylin agonists and uses thereof |
| US12371464B2 (en) | 2020-12-16 | 2025-07-29 | Medimmune Limited | Polypeptides and uses thereof |
-
2021
- 2021-12-15 US US17/551,701 patent/US12371464B2/en active Active
- 2021-12-15 EP EP21839935.0A patent/EP4263586A1/en active Pending
- 2021-12-15 MX MX2023007288A patent/MX2023007288A/es unknown
- 2021-12-15 CA CA3204296A patent/CA3204296A1/en active Pending
- 2021-12-15 KR KR1020237023385A patent/KR20230120134A/ko active Pending
- 2021-12-15 CR CR20230311A patent/CR20230311A/es unknown
- 2021-12-15 US US18/257,756 patent/US20240067693A1/en active Pending
- 2021-12-15 WO PCT/EP2021/086034 patent/WO2022129254A1/en not_active Ceased
- 2021-12-15 AU AU2021399076A patent/AU2021399076B2/en active Active
- 2021-12-15 CN CN202180084231.3A patent/CN116685599A/zh active Pending
- 2021-12-15 JP JP2023536144A patent/JP7767428B2/ja active Active
- 2021-12-15 IL IL303578A patent/IL303578A/en unknown
- 2021-12-16 AR ARP210103535A patent/AR124391A1/es unknown
- 2021-12-16 TW TW110147305A patent/TW202241933A/zh unknown
-
2023
- 2023-06-14 CL CL2023001719A patent/CL2023001719A1/es unknown
- 2023-07-06 CO CONC2023/0009066A patent/CO2023009066A2/es unknown
- 2023-07-12 EC ECSENADI202352600A patent/ECSP23052600A/es unknown
-
2024
- 2024-10-03 AU AU2024227071A patent/AU2024227071A1/en active Pending
-
2025
- 2025-02-12 US US19/052,168 patent/US20250289860A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP23052600A (es) | 2023-08-31 |
| AR124391A1 (es) | 2023-03-22 |
| AU2021399076B2 (en) | 2024-07-11 |
| US20220204580A1 (en) | 2022-06-30 |
| CN116685599A (zh) | 2023-09-01 |
| AU2024227071A1 (en) | 2024-10-24 |
| JP2023554046A (ja) | 2023-12-26 |
| AU2021399076A1 (en) | 2023-07-27 |
| US12371464B2 (en) | 2025-07-29 |
| US20240067693A1 (en) | 2024-02-29 |
| MX2023007288A (es) | 2023-07-03 |
| KR20230120134A (ko) | 2023-08-16 |
| IL303578A (en) | 2023-08-01 |
| AU2021399076A9 (en) | 2024-07-18 |
| US20250289860A1 (en) | 2025-09-18 |
| CO2023009066A2 (es) | 2023-07-10 |
| CR20230311A (es) | 2023-09-01 |
| CA3204296A1 (en) | 2022-06-23 |
| TW202241933A (zh) | 2022-11-01 |
| WO2022129254A1 (en) | 2022-06-23 |
| EP4263586A1 (en) | 2023-10-25 |
| JP7767428B2 (ja) | 2025-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23052600A (es) | Polipéptidos y usos de los mismos | |
| MX2022006365A (es) | Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos. | |
| CL2019002132A1 (es) | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinético y sus usos. | |
| ECSP20026986A (es) | Composiciones de péptidos tau fosforilados y sus usos | |
| PE20160991A1 (es) | Bioconjugados de polipeptidos de apelina sintetica | |
| MX388822B (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| MX2019012198A (es) | Constructos de polipéptidos multiespecíficos que tienen unión limitada a cd3 y métodos de utilización de los mismos. | |
| CR9570A (es) | Formulaciones y usos del peptido receptor de eritropoyetina | |
| CL2022001227A1 (es) | Agonistas del receptor npy2 | |
| PE20220488A1 (es) | Variantes del cnp y sus conjugados | |
| CO2019013768A2 (es) | Compuestos de mic-1 y usos de estos | |
| DOP2023000010A (es) | Agonistas del receptor npy2 solubles | |
| CU20170112A7 (es) | Variantes de polipeptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, así como procedimientos para la división de toxinas de fusarium | |
| AR096927A1 (es) | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7 | |
| MX2023010508A (es) | Composiciones que comprenden un polipéptido variante y usos de las mismas. | |
| CO2020013221A2 (es) | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos | |
| MX2018014198A (es) | Secuencias de envolturas de flavivirus variante y usos de las mismas. | |
| CO2024016693A2 (es) | Péptido con actividad antimicrobiana | |
| ES2058176T3 (es) | Un procedimiento para preparar un derivado peptidico. | |
| ES2054732T3 (es) | Un procedimiento para preparar un derivado peptidico. | |
| CL2023002583A1 (es) | Ligandos peptídicos del receptor 3 de somatostatina restringidos conformacionales y sus conjugados y sus usos. | |
| BR112018072968A2 (pt) | peptídeos monolipidados resistentes às proteases | |
| PE20220296A1 (es) | Virus del dengue atenuados | |
| MX2019000554A (es) | Factor vii de coagulación de acción prolongada y métodos para producir el mismo. | |
| CO2024015213A2 (es) | Péptido con actividad antimicrobiana |